Skip to main content

Table 1 Comparison of demographic and therapeutic characteristics of stage IIB/C and stage IIIA

From: Poor survival in stage IIB/C (T4N0) compared to stage IIIA (T1-2 N1, T1N2a) colon cancer persists even after adjusting for adequate lymph nodes retrieved and receipt of adjuvant chemotherapy

  Before matching After matching
Variable Stage IIB/C Stage IIIA P Stage IIB/C Stage IIIA P
No. of patients (%) 18,609 (53.2) 16,390 (46.8)   11,409 (50.0) 11,409 (50.0)  
Age    <.0001    0.94
 18–49 1,678 (9.0) 1424 (8.7) 935 (8.2) 920 (8.1)
 50–64 4,628 (24.9) 5284 (32.2) 2,979 (26.1) 3,016 (26.4)
 65–74 4,368 (23.5) 4419 (27.0) 2,957 (25.9) 2,956 (25.9)
 75 and more 7,935 (42.6) 5263 (32.1) 4,538 (39.8) 4,517 (39.6)
Distance from cancer reporting facility    0.06    0.58
 <50 miles 16,909 (92.9) 15,015 (93.4) 10,630 (93.2) 10,651 (93.4)
 ≥50 miles 1,303 (7.2) 1,066 (6.6) 779 (6.8) 758 (6.6)
Race/Ethnicity    <.0001    0.93
 White 15,964 (86.5) 13,450 (82.8)   9,785 (85.8) 9,770 (85.6)
 Black 1,965 (10.6) 2,197 (13.5)   1,283 (11.3) 1,308 (11.5)
 American Indian, Aleutian, or Eskimo 53 (0.3) 36 (0.2)   27 (0.2) 31 (0.3)
 Asian or Pacific Islander 390 (2.1) 456 (2.8)   261 (2.3) 251 (2.2)
 Other 89 (0.5) 100 (0.6)   53 (0.5) 49 (0.4)
Facility Type    0.02    0.90
 Community cancer program 2,715 (14.6) 2,239 (13.7) 1,565 (13.7) 1,588 (13.9)
 Comprehensive community cancer center 11,044 (59.4) 9,700 (59.2) 6,815 (59.7) 6,804 (59.6)
 Academic research program 4,825 (25.9) 4,432 (27.0) 3,029 (26.6) 3,017 (26.4)
 Other specified types of cancer program 25 (0.1) 19 (0.1)   
Facility Location    <.0001    0.99
 New England 1,335 (7.2) 886 (5.4) 678 (5.9) 692 (6.1)
 Mid Atlantic 2,971 (16.0) 2,402 (14.7) 1,814 (15.9) 1,809 (15.9)
 South Atlantic 3,835 (20.6) 3,715 (22.7) 2,352 (20.6) 2,391 (21.0)
 East North Central 3,580 (19.2) 3,127 (19.1) 2,174 (19.1) 2,201 (19.3)
 East South Central 1,162 (6.2) 1,186 (7.2) 788 (6.9) 786 (6.9)
 West North Central 1,555 (8.4) 1,333 (8.1) 1,035 (9.1) 1,002 (8.8)
 West South Central 1,487 (8.0) 1,391 (8.5) 942 (8.3) 938 (8.2)
 Mountain 779 (4.2) 678 (4.1) 440 (3.9) 438 (3.8)
 Pacific 1,905 (10.2) 1,672 (10.2) 1,186 (10.4) 1,152 (10.1)
Urban/Rural Location    0.05    0.96
 Metro ≥1 million 9,488 (53.0) 8,380 (53.1) 6,039 (52.9) 6,028 (52.8)
 Metro 250 k to 1 million 3,863 (21.6) 3,556 (22.5) 2,539 (22.3) 2,554 (22.4)
 Urban <250 k 1,766 (9.9) 1,516 (9.6) 1,104 (9.7) 1,112 (9.8)
 Urban ≥ 20 k adjacent metro 731 (4.1) 657 (4.2) 460 (4.0) 476 (4.2)
 Urban ≥ 20 k not adjacent metro 262 (1.5) 221 (1.4) 182 (1.6) 175 (1.5)
 Urban <20 k adjacent metro 957 (5.4) 751 (4.8) 577 (5.1) 572 (5.0)
 Urban <20 k not adjacent metro 454 (2.5) 387 (2.5) 286 (2.5) 258 (2.3)
 Rural <2500 adjacent metro 164 (0.9) 169 (1.1) 108 (1.0) 109 (1.0)
 Rural <2500 not adjacent metro 212 (1.2) 154 (1.0) 114 (1.0) 125 (1.1)
Comorbidities    <.0001    0.61
 0 12,872 (69.2) 11,665 (71.2) 7,905 (69.3) 7,962 (69.8)
 1 4,185 (22.5) 3,537 (21.6) 2,576 (22.6) 2,513 (22.0)
 2 1,552 (8.3) 1,188 (7.3) 928 (8.1) 934 (8.2)
Primary Site    <.0001    0.99
 Cecum 4,917 (26.4) 3,941 (24.1) 3,077 (27.0) 3,077 (27.0)
 Ascending Colon 2,876 (15.5) 3,140 (19.2) 1,969 (17.3) 1,992 (17.5)
 Hepatic Flexure 748 (4.0) 608 (3.7) 473 (4.2) 461 (4.0)
 Transverse Colon 2,061 (11.1) 1,154 (7.0) 1,031 (9.0) 991 (8.7)
 Splenic Flexure 786 (4.2) 366 (2.2) 312 (2.7) 327 (2.9)
 Descending Colon 1,161 (6.2) 960 (5.9) 705 (6.2) 706 (6.2)
 Sigmoid Colon 5,324 (28.6) 5,756 (35.1) 3,524 (30.9) 3,535 (31.0)
 Overlapping Lesions 369 (2.0) 140 (0.9) 120 (1.1) 121 (1.1)
 Not Otherwise Specified 367 (2.0) 325 (2.0) 198 (1.7) 199 (1.7)
Grade    <.0001    0.87
 Well differentiated 1,506 (8.4) 1,779 (11.4) 1,087 (9.5) 1,084 (9.5)
 Moderately differentiated 11,868 (66.0) 11,226 (71.9) 8,007 (70.2) 8,049 (70.6)
 Poorly differentiated 4,004 (22.3) 2,381 (15.3) 2,084 (18.3) 2,059 (18.1)
 Undifferentiated, anaplastic 611 (3.4) 230 (1.5) 231 (2.0) 217 (1.9)
Surgical Margins    <.0001    0.87
 No residual tumor 14992 (82.6) 16,012 (98.8) 11,243 (98.6) 11,246 (98.6)
 With Residual tumor 3156 (17.4) 190 (1.2) 166 (1.5) 163 (1.4)
Regional Lymph Nodes Examined    <.0001    <.0001
 0–11 4,399 (23.8) 4,867 (29.9) 2,422 (21.3) 3,298 (29.0)
 12–90 14,101 (76.2) 11,434 (70.1) 8,944 (78.7) 8,078 (71.0)
Chemotherapy    <.0001    <.0001
 None 10,423 (58.7) 4,807 (30.5) 6,362 (58.4) 3,659 (33.3)
 Yes 7,335 (41.3) 10,975 (69.5) 4,525 (41.6) 7,327 (66.7)